Lakshminarayan R Ranganath

List of Publications by Year
in descending order

88	2,254	218677	243625
papers	citations	26 h-index	44 g-index

91	91	91	1159
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and safety of recombinant human parathyroid hormone (1â€“84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes and Endocrinology,the, 2013, 1, 275-283.	11.4	244
2	Recent advances in management of alkaptonuria (invited review; best practice article). Journal of Clinical Pathology, 2013, 66, 367-373.	2.0	126
3	Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4â€...weeks of treatment. Annals of the Rheumatic Diseases, 2016, 75, 362-367.	0.9	123
4	Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Molecular Genetics and Metabolism, 2018, 125, 127-134.	1.1	89
5	Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Annals of the Rheumatic Diseases, 2014, 73, 284-289.	0.9	88
6	Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on â€˜black bone diseaseâ€™ in Italy. European Journal of Human Genetics, 2016, 24, 66-72.	2.8	87
7	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 762-772.	11.4	78
8	Natural history of alkaptonuria revisited: analyses based on scoring systems. Journal of Inherited Metabolic Disease, 2011, 34, 1141-1151.	3.6	69
9	Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology, 2010, 49, 1412-1414.	1.9	62
10	Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology, 2011, 50, 271-277.	1.9	62
11	Urine homogentisic acid and tyrosine: Simultaneous analysis by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 963, 106-112.	2.3	54
12	Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotypeâ€“phenotype correlations in the largest cohort of patients with AKU. European Journal of Human Genetics, 2019, 27, 888-902.	2.8	54
13	A quantitative assessment of alkaptonuria. Journal of Inherited Metabolic Disease, 2011, 34, 1153-1162.	3.6	48
14	Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Annals of Clinical Biochemistry, 2015, 52, 597-605.	1.6	46
15	Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis and Cartilage, 2012, 20, 880-886.	1.3	45
16	The entero-insular axis: implications for human metabolism. Clinical Chemistry and Laboratory Medicine, 2008, 46, 43-56.	2.3	42
17	Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations. JIMD Reports, 2014, 24, 3-11.	1.5	42
18	Cardiovascular manifestations of Alkaptonuria. Journal of Inherited Metabolic Disease, 2011, 34, 1177-1181.	3.6	40

#	Article	IF	Citations
19	Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice. JIMD Reports, 2015, 24, 45-50.	1.5	40
20	Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the diseaseâ€"A review. Journal of Inherited Metabolic Disease, 2019, 42, 776-792.	3.6	40
21	The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool. Annals of Clinical Biochemistry, 2017, 54, 323-330.	1.6	39
22	The Role of Nitisinone in Tyrosine Pathway Disorders. Current Rheumatology Reports, 2014, 16, 457.	4.7	36
23	Alkaptonuria: An example of a â€œfundamental diseaseâ€â€"A rare disease with important lessons for more common disorders. Seminars in Cell and Developmental Biology, 2016, 52, 53-57.	5.0	36
24	Pigmentation Chemistry and Radicalâ€Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage. Angewandte Chemie - International Edition, 2020, 59, 11937-11942.	13.8	34
25	Alkaptonuria: Current Perspectives . The Application of Clinical Genetics, 2020, Volume 13, 37-47.	3.0	34
26	Acute peripheral administration of synthetic human GLP-1 (7â€"36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?. Regulatory Peptides, 2013, 183, 54-61.	1.9	29
27	Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria. JIMD Reports, 2015, 24, 21-27.	1.5	26
28	Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing. Rheumatology, 2017, 56, 156-164.	1.9	25
29	Identification of trabecular excrescences, novel microanatomical structures, present in bone in osteoarthropathies. , 2012, 23, 300-309.		25
30	Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects. Clinical Chemistry and Laboratory Medicine, 2015, 53, e81-3.	2.3	21
31	Alkaptonuria â€" Many questions answered, further challenges beckon. Annals of Clinical Biochemistry, 2020, 57, 106-120.	1.6	21
32	Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 259-268.	3.6	21
33	Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria. Clinical Biochemistry, 2014, 47, 640-647.	1.9	20
34	Lessons from rare diseases of cartilage and bone. Current Opinion in Pharmacology, 2015, 22, 107-114.	3.5	20
35	Nitisinone causes acquired tyrosinosis in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 1014-1023.	3.6	20
36	Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 737-747.	3.6	18

#	Article	IF	Citations
37	Evaluation of the Mitra microsampling device for use with key urinary metabolites in patients with Alkaptonuria. Bioanalysis, 2018, 10, 1919-1932.	1.5	17
38	A new integrated and interactive tool applicable to inborn errors of metabolism: Application to alkaptonuria. Computers in Biology and Medicine, 2018, 103, 1-7.	7.0	17
39	Inflammatory and oxidative stress biomarkers in alkaptonuria: data from the DevelopAKUre project. Osteoarthritis and Cartilage, 2018, 26, 1078-1086.	1.3	17
40	A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria. Clinical Chemistry, 2019, 65, 530-539.	3.2	17
41	Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria. Human Molecular Genetics, 2019, 28, 3928-3939.	2.9	16
42	Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone. Molecular Genetics and Metabolism, 2018, 125, 135-143.	1.1	15
43	Subclinical ochronosis features in alkaptonuria: a cross-sectional study. BMJ Innovations, 2019, 5, 82-91.	1.7	15
44	Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre. JIMD Reports, 2020, 55, 75-87.	1.5	13
45	Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism. Genes and Diseases, 2022, 9, 1129-1142.	3.4	13
46	Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LCâ€QTOFâ€MS. JIMD Reports, 2019, 48, 67-74.	1.5	11
47	Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury. CKJ: Clinical Kidney Journal, 2015, 8, 109-112.	2.9	10
48	Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone. Data in Brief, 2018, 20, 1620-1628.	1.0	10
49	A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Reports, 2020, 53, 71-79.	1.5	10
50	Alkaptonuria Severity Score Index Revisited: Analysing theÂAKUSSI and Its Subcomponent Features. JIMD Reports, 2018, 41, 53-62.	1.5	9
51	Age-Related Deviation of Gait from Normality in Alkaptonuria. JIMD Reports, 2015, 24, 39-44.	1.5	8
52	Interpreting sources of variation in clinical gait analysis: A case study. Gait and Posture, 2017, 52, 1-4.	1.4	8
53	Living with alkaptonuria. BMJ: British Medical Journal, 2011, 343, d5155-d5155.	2.3	7
54	Reduction of frontal plane knee load caused by lateral trunk lean depends on step width. Gait and Posture, 2018, 61, 483-487.	1.4	7

#	Article	IF	Citations
55	Raman Spectroscopy identifies differences in ochronotic and non-ochronotic cartilage; a potential novel technique for monitoring ochronosis. Osteoarthritis and Cartilage, 2019, 27, 1244-1251.	1.3	7
56	Anatomical Distribution of Ochronotic Pigment in Alkaptonuric Mice is Associated with Calcified Cartilage Chondrocytes at Osteochondral Interfaces. Calcified Tissue International, 2021, 108, 207-218.	3.1	7
57	Vitiligo, alkaptonuria, and nitisinoneâ€"A report of three families and review of the literature. JIMD Reports, 2021, 61, 25-33.	1.5	7
58	Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuriaâ€"An approach using statistical modelling. JIMD Reports, 2022, 63, 80-92.	1.5	7
59	Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium. Orphanet Journal of Rare Diseases, 2021, 16, 510.	2.7	7
60	What does the arthropathy of alkaptonuria teach us about disease mechanisms in osteoarthritis and ageing of joints?. Rheumatology, 2016, 55, 1151-1152.	1.9	6
61	Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients. Journal of Inherited Metabolic Disease, 2021, 44, 666-676.	3.6	6
62	Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients. Molecular Genetics and Metabolism, 2021, 133, 324-331.	1.1	6
63	Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria. Molecular Genetics and Metabolism Reports, 2022, 30, 100846.	1.1	6
64	Longâ€term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression. JIMD Reports, 2022, 63, 221-230.	1.5	6
65	Method development and validation for analysis of phenylalanine, 4â€hydroxyphenyllactic acid and 4â€hydroxyphenylpyruvic acid in serum and urine. JIMD Reports, 0, , .	1.5	6
66	Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients. JIMD Reports, 2022, 63, 351-360.	1.5	6
67	Temporal adaptations in the phenylalanine/tyrosine pathway and related factors during nitisinone-induced tyrosinaemia in alkaptonuria. Molecular Genetics and Metabolism, 2022, , .	1.1	6
68	Concentric lamellae â€“ novel microanatomical structures in the articular calcified cartilage of mice. Scientific Reports, 2019, 9, 11188.	3.3	5
69	Effects of a proteinâ€restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria. JIMD Reports, 2022, 63, 41-49.	1.5	4
70	Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria. Metabolites, 2022, 12, 477.	2.9	4
71	Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria â€“ Is nitisinone the solution?. Molecular Genetics and Metabolism Reports, 2020, 23, 100588.	1.1	3
72	Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2â€dioxygenase deficiency in the liver is responsible for homogentisic acidâ€derived ochronotic pigmentation. JIMD Reports, 2021, 58, 52-60.	1.5	3

#	Article	IF	Citations
73	Development of an effective therapy for alkaptonuria â€“ Lessons for osteoarthritis. Rheumatology and Immunology Research, 2021, 2, 79-85.	0.8	3
74	Characterising the arthroplasty in spondyloarthropathy in a large cohort of eightyâ€seven patients with alkaptonuria. Journal of Inherited Metabolic Disease, 2021, 44, 656-665.	3.6	3
75	Treatment of osteoporotic fractures in alkaptonuria by teriparatide stimulates bone formation and decreases fracture rate â€“ A report of two cases. Bone Reports, 2021, 15, 101151.	0.4	3
76	Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index. JIMD Reports, 2022, 63, 361-370.	1.5	3
77	Deposition of ochronotic pigment in articular cartilage in alkaptonuria is initiated near the tidemark and progresses to the articular surface. Bone, 2010, 47, S79.	2.9	2
78	Raman spectroscopy can non-invasively distinguish between ochronotic and non-ochronotic cartilage. Osteoarthritis and Cartilage, 2018, 26, S105.	1.3	2
79	Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. Clinical Biochemistry, 2019, 71, 24-30.	1.9	2
80	â€œLessons from Rare Forms of Osteoarthritisâ€• Calcified Tissue International, 2021, 109, 291-302.	3.1	2
81	Diagnostic tools and strategies for assessing disease progression in Alkaptonuria. Expert Opinion on Orphan Drugs, 2015, 3, 705-717.	0.8	1
82	Disruption of collagen triple helix hydrogen bonding in ochronotic human cartilage in alkaptonuria observed by dynamic nuclear polarisation-enhanced solid-state nuclear magnetic resonance spectroscopy. Osteoarthritis and Cartilage, 2018, 26, S99.	1.3	1
83	The contribution of mouse models in the rare disease alkaptonuria. Drug Discovery Today: Disease Models, 2020, 31, 37-43.	1.2	1
84	Identifying joint-specific gait mechanisms causing impaired gait in alkaptonuria patients. Gait and Posture, 2022, 91, 312-317.	1.4	1
85	192.â€ƒDevelopment of Osteoarthritis in Alkaptonuric Mice. Rheumatology, 2014, 53, i131-i131.	1.9	0
86	Pigmentierungschemie und radikalbasierter Kollagenabbau bei Alkaptonurie und Arthrose. Angewandte Chemie, 2020, 132, 12035-12040.	2.0	0
87	Innentitelbild: Pigmentierungschemie und radikalbasierter Kollagenabbau bei Alkaptonurie und Arthrose (Angew. Chem. 29/2020). Angewandte Chemie, 2020, 132, 11770-11770.	2.0	0
88	A case report of pregnancy in untreated alkaptonuria â€“ Focus on urinary tissue remodelling markers. Molecular Genetics and Metabolism Reports, 2021, 27, 100766.	1.1	0